Shareholders alert for Myriad Genetics Inc.

M2 Presswire, February, 2007

M2 PRESSWIRE-6 February 2007-Biotech News: Shareholders alert for Myriad Genetics Inc(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:06022007 Shareholders alert for Myriad Genetics Inc (NASDAQ:MYGN) There are a myriad of diseases out there, and Myriad Genetics is working on figuring out which ones you will get.

Its tests can determine a patient's risk for breast or ovarian cancer (BRACAnalysis), skin cancer (MELARIS), and colon cancer (COLARIS). The company is also developing treatments for some of those myriad diseases. With such partners as Abbott Laboratories and the National Institutes of Health, Myriad is developing drugs for Alzheimer's disease, cancers, and viral disease. Its lead drug candidate Flurizan is in late-stage clinical trials as a treatment for...